1,890 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Ransom Advisory Ltd

Ransom Advisory Ltd purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,890 shares of the medical equipment provider’s stock, valued at approximately $214,000.

Several other hedge funds have also recently modified their holdings of the stock. Garde Capital Inc. purchased a new stake in Zimmer Biomet during the 1st quarter valued at about $29,000. Washington Trust Advisors Inc. purchased a new stake in Zimmer Biomet during the 1st quarter valued at about $30,000. Columbia River Financial Group LLC purchased a new stake in Zimmer Biomet during the 1st quarter valued at about $30,000. Menard Financial Group LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at about $30,000. Finally, Accent Capital Management LLC purchased a new stake in Zimmer Biomet during the 1st quarter valued at about $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $102.33 on Thursday. The firm has a 50 day simple moving average of $99.06 and a 200-day simple moving average of $99.63. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The stock has a market cap of $20.27 billion, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same quarter in the prior year, the company posted $2.01 EPS. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Analyst Ratings Changes

ZBH has been the subject of several research reports. UBS Group upped their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Raymond James Financial upped their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada increased their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $111.00.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.39% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.